A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study Meeting Abstract

  

Authors:	Gao, X.; Smith, M. R.; Scher, H. I.; Verholen, F.; Adorjan, P.; Dissanayake, M.; Laccetti, A. L.
Abstract Title:	A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study
Meeting Title:	2023 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	41
Issue:	16 Suppl.
Meeting Dates:	2023 Jun 2-6
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2023-06-01
Language:	English
DOI:	10.1200/JCO.2023.41.16_suppl.TPS5111
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=cin20&AN=164018281&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	Meeting Abstract: TPS5111 -- Meeting was also available virtually -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/209678